Women with breast cancer leptomeningeal metastases are needed for a study to research an experimental cellular therapy.

IRB/UVA Tracking #
20805
Principal Investigator
Camilo Fadul
Contact
Jungeun Kim
Contact Email
Contact Phone
434.982.0074
Official Trial Title
A Phase I Study of Anti-CD3 x Anti-Her2/neu (Her2-Bi) Armed Activated T Cells (ATC) in Patients with Breast Cancer Leptomeningeal Metastases
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are women ages 18 and over, and have breast cancer leptomeningeal metastases. The purpose of this study to evaluate an experimental drug (HER2-BATs) in patients with breast cancer leptomeningeal metastases. The experimental drug dose, safety, and the effects of the drug will be evaluated for this study.

Participation is approximately 21 visits over 4 months. This includes a screening period, leukapheresis procedure, 3-4 weeks of chemotherapy, 8 weeks of study drug treatment and possibly longer, and 4 additional follow-up clinic visits. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03661424

Compensation

This study does not offer compensation; Reimbursement: You may stay in hotel accommodations arranged by the study team if you live over 40 minutes away.